Engineered SOX17 Reprogramming Somatic Cells to Totipotent Stem States
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reprogramming human somatic cells into pluripotent stem cells are inefficient, slow, and lack reproducibility, and human embryonic stem cells are inadequate for studying early human development and infertility-related diseases due to their limited ability to generate extra-embryonic tissues.
Innovation Solution
The use of an engineered SOX17 transcription factor combined with OCT4 and KLF4 to reprogram human somatic cells into induced expanded potential stem cells (iEPSCs) and induced neural stem cells (iNSCs), which are cultured in a specific medium to enhance efficiency and totipotency-like features.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional Yamanaka factors (OCT4, SOX2, KLF4, C-MYC) are used for reprogramming, then pluripotent stem cells can be generated, but the process is slow and has low efficiency
Solution Approach 1:
The patent changes the transcriptional parameter by replacing SOX2 with engineered SOX17 factors (eSOX17), which fundamentally alters the reprogramming mechanism to achieve faster and more efficient conversion of somatic cells to totipotent-like states
Solution Approach 2:
The engineered SOX17 factors act as intermediaries that bridge somatic cells and totipotent-like states, facilitating the reprogramming process through specific molecular interactions that accelerate cell fate conversion
2Reliability
If traditional reprogramming methods are used, then pluripotent stem cells can be generated, but reproducibility is poor
Solution Approach 1:
The patent modifies the transcriptional parameter by introducing engineered SOX17 factors with specific mutations (e.g., E57V, E57A) that enhance binding affinity and transcriptional activity, leading to more consistent and reproducible reprogramming outcomes across different cell types and passages
Solution Approach 2:
The patent employs feedback mechanisms through optimized culture conditions and transcription factor dosing that monitor and adjust the reprogramming process, improving reproducibility by maintaining optimal conditions throughout cell conversion
3Adaptability or versatility
If human embryonic stem cells are used, then self-renewal capacity is maintained, but the ability to generate extra-embryonic tissues is limited
Solution Approach 1:
The patent inverts the traditional approach by not using human embryos to study early development, but instead using reprogrammed totipotent-like cells derived from somatic cells, which can generate extra-embryonic tissues and provide an alternative model system
Solution Approach 2:
The patent changes the cell state parameter by inducing totipotency-like features in reprogrammed cells through engineered SOX17 factors, enabling these cells to generate extra-embryonic tissues and model early human development more accurately
Data Source
AI summary
Compositions of transcription factor cocktails including engineered SOX17 factor (eSOX17), together with one or more of OCT4, KLF4, and C-MYC, and vectors carrying one or more of these transcription factors suitable for delivery to donor somatic cells for generating induced expanded potential stem cells (iEPSCs) or induced neural stem cells (iNSCs) are provided. The disclosed compositions deliver reprograming of human somatic cells into a totipotency-like, or multipotency-like state with improved efficiency. Compositions of eSOX17-derived iEPSCs and iNSCs generated according to the described methods are also described. The methods engineer somatic cells to express one or more markers of pluripotency or neural stem cells. Methods of using iEPSCs or iNSCs in studying early human development and in cell therapy are also provided.